Business & Finance
Aeterna Zentaris reports loss of $0.12 per share
Published in Healthcare Finance, Tax and Law Weekly, December 13th, 2006
"The third quarter was marked by significant progress with the clinical development of our luteinizing hormone-releasing hormone (LHRH) antagonist compound, ozarelix, for which we disclosed positive phase II results in both prostate cancer and benign prostatic hyperplasia," said Gilles Gagnon, Aeterna Zentaris' president and CEO. "These very encouraging results enable us to pursue ozarelix's clinical development in both indications, moving forward with an ongoing phase IIb trial in prostate cancer as well as the potential to initiate a late-stage...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Finance, Tax and Law Weekly
More Articles from Healthcare Finance, Tax and Law Weekly
- Business & Finance
Acusphere reports on operational progress, posts loss of $0.46 per share - Business & Finance
Adventrx reports loss from operations of $5.1 million - Business & Finance
Aksys reports 48% decrease in revenue - Business & Finance
Alexza updates status of development pipeline, posts $11.2 million net loss - Business & Finance
Amarin posts net loss of $0.09 per share, provides Miraxion development update - Business & Finance
American Independence reports $0.01 million in income, enters fully-insured health market - More from this issue of Healthcare Finance, Tax and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
